Download PDF
Thromb Haemost 2018; 118(12): 2037-2045
DOI: 10.1055/s-0038-1675600
Coagulation and Fibrinolysis
Georg Thieme Verlag KG Stuttgart · New York

Proline 36 of the Factor XIII Activation Peptide Plays a Crucial Role in Substrate Recognition and Zymogen Activation

Bojun Li
1   Experimental Haemostasis Group, Department for BioMedical Research, University of Bern, Bern, Switzerland
,
Ramya Billur
2   Department of Chemistry, University of Louisville, Louisville, Kentucky, United States
,
Muriel C. Maurer
2   Department of Chemistry, University of Louisville, Louisville, Kentucky, United States
,
Hans P. Kohler
1   Experimental Haemostasis Group, Department for BioMedical Research, University of Bern, Bern, Switzerland
,
Pascale Raddatz Müller
3   Division of Haematology and Central Haematology Laboratory, Luzerner Kantonsspital, Lucerne, Switzerland
,
Lorenzo Alberio
4   Division of Haematology and Central Haematology Laboratory, Lausanne University Hospital, Lausanne, Switzerland
5   Faculté de Biologie et Médecine, University of Lausanne, Lausanne, Switzerland
,
Verena Schroeder
1   Experimental Haemostasis Group, Department for BioMedical Research, University of Bern, Bern, Switzerland
› Author Affiliations Funding This work was supported by grants from the Swiss National Science Foundation (Grant 310030_169220; awarded to H.P.K. and V.S.) and the National Institutes of Health (Grant R15 HL120068; awarded to M.C.M.).
Further Information

Publication History

03 July 2018

27 September 2018

Publication Date:
12 November 2018 (online)

    Permissions and Reprints

Abstract

The activation peptide of blood coagulation factor XIII (AP-FXIII) has important functions in stabilizing the FXIII-A2 dimer and regulating FXIII activation. Contributions of many of its 37 amino acids to these functions have been described. However, the role of proline 36, which is adjacent to the thrombin cleavage site at Arg37, has not yet been studied in detail. We approached this question when we came across a patient with congenital FXIII deficiency in whom we detected a novel Pro36Ser mutation. We expressed the mutant FXIII-A Pro36Ser protein in Chinese hamster ovary cells and found that this mutation does not influence FXIII-A expression but significantly inhibits proteolytic activation by thrombin. The enzymatic transglutaminase activity is not affected as it can be induced in the presence of high Ca2+ concentrations. We performed nuclear magnetic resonance analysis to investigate AP-FXIII–thrombin interactions, which showed that the mutant Ser36 peptide binds less well to the thrombin surface than the native Pro36 peptide. The Arg37 at the P1 position still makes strong interactions with the active site cleft but the P4–P2 residues (34VVS36) appear to be less well positioned to contact the neighbouring thrombin active site region. In conclusion, we have characterized a novel mutation in AP-FXIII representing only the fourth case of the rare FXIII-A type II deficiency. This case served as a perfect in vivo model to shed light on the crucial role of Pro36 in the proteolytic activation of FXIII-A. Our results contribute to the understanding of structure–function relationship in FXIII.

Keywords

coagulation factor XIII - factor XIII activation peptide - congenital factor XIII deficiency

Authors' Contributions

B.L., R.B. and M.C.M. performed the experiments; B.L., R.B., M.C.M. and V.S. analysed the results and prepared the figures; P.R.M. and L.A. characterized the patient; H.P.K. and V.S. designed the research; B.L., R.B., M.C.M. and V.S. wrote the paper; all authors revised the manuscript.


Supplementary Material

 

  • References

  • 1 Muszbek L, Bereczky Z, Bagoly Z, Komáromi I, Katona É. Factor XIII: a coagulation factor with multiple plasmatic and cellular functions. Physiol Rev 2011; 91 (03) 931-972
    CrossrefPubMedGoogle Scholar
  • 2 Schroeder V, Vuissoz JM, Caflisch A, Kohler HP. Factor XIII activation peptide is released into plasma upon cleavage by thrombin and shows a different structure compared to its bound form. Thromb Haemost 2007; 97 (06) 890-898
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Komáromi I, Bagoly Z, Muszbek L. Factor XIII: novel structural and functional aspects. J Thromb Haemost 2011; 9 (01) 9-20
    CrossrefPubMedGoogle Scholar
  • 4 Credo RB, Curtis CG, Lorand L. Ca2+-related regulatory function of fibrinogen. Proc Natl Acad Sci U S A 1978; 75 (09) 4234-4237
    CrossrefPubMedGoogle Scholar
  • 5 Hornyak TJ, Shafer JA. Role of calcium ion in the generation of factor XIII activity. Biochemistry 1991; 30 (25) 6175-6182
    CrossrefPubMedGoogle Scholar
  • 6 Kristiansen GK, Andersen MD. Reversible activation of cellular factor XIII by calcium. J Biol Chem 2011; 286 (11) 9833-9839
    CrossrefPubMedGoogle Scholar
  • 7 Muszbek L, Haramura G, Polgár J. Transformation of cellular factor XIII into an active zymogen transglutaminase in thrombin-stimulated platelets. Thromb Haemost 1995; 73 (04) 702-705
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Yee VC, Pedersen LC, Le Trong I, Bishop PD, Stenkamp RE, Teller DC. Three-dimensional structure of a transglutaminase: human blood coagulation factor XIII. Proc Natl Acad Sci U S A 1994; 91 (15) 7296-7300
    CrossrefPubMedGoogle Scholar
  • 9 Handrkova H, Schroeder V, Kohler HP. The activation peptide of coagulation factor XIII is vital for its expression and stability. J Thromb Haemost 2015; 13 (08) 1449-1458
    CrossrefPubMedGoogle Scholar
  • 10 Gallwitz M, Enoksson M, Thorpe M, Hellman L. The extended cleavage specificity of human thrombin. PLoS One 2012; 7 (02) e31756
    CrossrefPubMedGoogle Scholar
  • 11 MacArthur MW, Thornton JM. Influence of proline residues on protein conformation. J Mol Biol 1991; 218 (02) 397-412
    CrossrefPubMedGoogle Scholar
  • 12 Weiss MS, Metzner HJ, Hilgenfeld R. Two non-proline cis peptide bonds may be important for factor XIII function. FEBS Lett 1998; 423 (03) 291-296
    CrossrefPubMedGoogle Scholar
  • 13 Sadasivan C, Yee VC. Interaction of the factor XIII activation peptide with α -thrombin. Crystal structure of its enzyme-substrate analog complex. J Biol Chem 2000; 275 (47) 36942-36948
    CrossrefPubMedGoogle Scholar
  • 14 Guex N, Peitsch MC. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 1997; 18 (15) 2714-2723
    CrossrefPubMedGoogle Scholar
  • 15 Ariëns RA, Kohler HP, Mansfield MW, Grant PJ. Subunit antigen and activity levels of blood coagulation factor XIII in healthy individuals. Relation to sex, age, smoking, and hypertension. Arterioscler Thromb Vasc Biol 1999; 19 (08) 2012-2016
    CrossrefPubMedGoogle Scholar
  • 16 Borhany M, Handrkova H, Cairo A. , et al. Congenital factor XIII deficiency in Pakistan: characterization of seven families and identification of four novel mutations. Haemophilia 2014; 20 (04) 568-574
    CrossrefPubMedGoogle Scholar
  • 17 Kohler HP, Ariëns RAS, Whitaker P, Grant PJ. A common coding polymorphism in the FXIII A-subunit gene (FXIIIVal34Leu) affects cross-linking activity. Thromb Haemost 1998; 80 (04) 704
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Bode W, Turk D, Karshikov A. The refined 1.9-A X-ray crystal structure of D-Phe-Pro-Arg chloromethylketone-inhibited human alpha-thrombin: structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationships. Protein Sci 1992; 1 (04) 426-471
    PubMedGoogle Scholar
  • 19 Dang QD, Sabetta M, Di Cera E. Selective loss of fibrinogen clotting in a loop-less thrombin. J Biol Chem 1997; 272 (32) 19649-19651
    CrossrefPubMedGoogle Scholar
  • 20 Ni F, Scheraga HA. Use of the transferred nuclear Overhauser effect to determine the conformations of ligands bound to proteins. Acc Chem Res 1994; 27: 257-264
    CrossrefPubMedGoogle Scholar
  • 21 Campbell AP, Sykes BD. The two-dimensional transferred nuclear Overhauser effect: theory and practice. Annu Rev Biophys Biomol Struct 1993; 22: 99-122
    CrossrefPubMedGoogle Scholar
  • 22 Kohler HP, Ichinose A, Seitz R, Ariens RAS, Muszbek L. ; Factor XIII And Fibrinogen SSC Subcommittee Of The ISTH. Diagnosis and classification of factor XIII deficiencies. J Thromb Haemost 2011; 9 (07) 1404-1406
    CrossrefPubMedGoogle Scholar
  • 23 Schroeder V, Kohler HP. Factor XIII: structure and function. Semin Thromb Hemost 2016; 42 (04) 422-428
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Kohler HP, Stickland MH, Ossei-Gerning N, Carter A, Mikkola H, Grant PJ. Association of a common polymorphism in the factor XIII gene with myocardial infarction. Thromb Haemost 1998; 79 (01) 8-13
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Trumbo TA, Maurer MC. Thrombin hydrolysis of V29F and V34L mutants of factor XIII (28-41) reveals roles of the P(9) and P(4) positions in factor XIII activation. Biochemistry 2002; 41 (08) 2859-2868
    CrossrefPubMedGoogle Scholar
  • 26 Isetti G, Maurer MC. Thrombin activity is unaltered by N-terminal truncation of factor XIII activation peptides. Biochemistry 2004; 43 (14) 4150-4159
    CrossrefPubMedGoogle Scholar
  • 27 Jadhav MA, Isetti G, Trumbo TA, Maurer MC. Effects of introducing fibrinogen Aalpha character into the factor XIII activation peptide segment. Biochemistry 2010; 49 (13) 2918-2924
    CrossrefPubMedGoogle Scholar
  • 28 Duval C, Ali M, Chaudhry WW, Ridger VC, Ariëns RAS, Philippou H. Factor XIII A-subunit V34L variant affects thrombus cross-linking in a murine model of thrombosis. Arterioscler Thromb Vasc Biol 2016; 36 (02) 308-316
    CrossrefPubMedGoogle Scholar
  • 29 Vindigni A, Dang QD, Di Cera E. Site-specific dissection of substrate recognition by thrombin. Nat Biotechnol 1997; 15 (09) 891-895
    CrossrefPubMedGoogle Scholar
  • 30 Le Bonniec BF, Myles T, Johnson T, Knight CG, Tapparelli C, Stone SR. Characterization of the P2′ and P3′ specificities of thrombin using fluorescence-quenched substrates and mapping of the subsites by mutagenesis. Biochemistry 1996; 35 (22) 7114-7122
    CrossrefPubMedGoogle Scholar
  • 31 Oshima G. Inhibition by calcium ions of thrombin. Thromb Res 1990; 58 (04) 383-393
    CrossrefPubMedGoogle Scholar
  • 32 Schroeder V, Kohler HP. Factor XIII deficiency: an update. Semin Thromb Hemost 2013; 39 (06) 632-641
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Morange P, Trigui N, Frère C. , et al. Molecular characterization of a novel mutation in the factor XIII a subunit gene associated with a severe defect: importance of prophylactic substitution. Blood Coagul Fibrinolysis 2009; 20 (07) 605-606
    CrossrefPubMedGoogle Scholar
  • 34 Thomas A, Biswas A, Dodt J. , et al. Coagulation factor XIIIA subunit missense mutations affect structure and function at the various steps of factor XIII action. Hum Mutat 2016; 37 (10) 1030-1041
    CrossrefPubMedGoogle Scholar
  • 35 Egbring R, Seitz R, Gürten GV, Köther M, Barthels M, Fuchs G. Bleeding complications in heterozygotes with congenital factor XIII deficiency. In: Mosesson MW. , ed. Fibrinogen—Biochemistry, Biological Functions, Gene Regulation and Expression. Amsterdam: Elsevier; 1988: 341-346
    Google Scholar
  • 36 Seitz R, Duckert F, Lopaciuk S, Muszbek L, Rodeghiero F, Seligsohn U. ; Study Group. ETRO Working Party on Factor XIII questionnaire on congenital factor XIII deficiency in Europe: status and perspectives. Semin Thromb Hemost 1996; 22 (05) 415-418
    Article in Thieme ConnectPubMedGoogle Scholar
  • 37 Mahmoodi M, Peyvandi F, Afrasiabi A, Ghaffarpasand F, Karimi M. Bleeding symptoms in heterozygous carriers of inherited coagulation disorders in southern Iran. Blood Coagul Fibrinolysis 2011; 22 (05) 396-401
    CrossrefPubMedGoogle Scholar
  • 38 Ivaskevicius V, Biswas A, Bevans C. , et al. Identification of eight novel coagulation factor XIII subunit A mutations: implied consequences for structure and function. Haematologica 2010; 95 (06) 956-962
    CrossrefPubMedGoogle Scholar
  • 39 Ivaskevicius V, Biswas A, Loreth R. , et al. Mutations affecting disulphide bonds contribute to a fairly common prevalence of F13B gene defects: results of a genetic study in 14 families with factor XIII B deficiency. Haemophilia 2010; 16 (04) 675-682
    PubMedGoogle Scholar